ClinicalTrials.gg
Not yet recruitingNCT07192263Updated Sep 25, 2025

Study to Evaluate the Efficacy and Safety of IN-B00009 Injection in Adults With Obesity or Overweight Without Diabetes Mellitus

A Phase 3 interventional study of IN-B00009 and Placebo in Obesity &Amp; Overweight, sponsored by HK inno.N Corporation. Not yet recruiting. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-25.

Sponsored by HK inno.N Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
19 Years to 75 Years
Sex
All
01

Study summary

This Phase 3 study is designed to evaluate the efficacy and safety of IN-B00009 injection in adults with obesity or overweight without diabetes mellitus

02

Conditions studied

  • Obesity &Amp; Overweight
03

In context

Obesity

11,556 studies on the registry are indexed under Obesity; 2,055 are open to participants now.

This study's planned enrollment of 300 is above the median of 67 across 9,036 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

HK inno.N Corporation is the lead sponsor of 104 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 19 to 75 years as of the date of written consent
  2. Those who meet any of the following obesity criteria at the screening visit

    • ≥ 30 kg/m2
    • 27 kg/m2 ≤ BMI \< 30 kg/m2 with at least one risk factor or comorbidity

      • BMI (kg/m2) = weight (kg) / height (m)2

        • Hypertension: Taking antihypertensive medication or sitSBP ≥ 140 mmHg or sitDBP ≥ 90 mmHg
        • Dyslipidemia: Taking dyslipidemia medication or Total Cholesterol ≥ 240mg/dL or LDL-C ≥ 160 mg/dL or TG ≥ 200 mg/dL or HDL-C \< 40 mg/dL
        • Obstructive sleep apnea
        • Cardiovascular and cerebrovascular diseases: Ischemic cardiovascular and cerebrovascular diseases not corresponding to exclusion criterion 17, heart failure of Class I to III, etc.
        • Prediabetes: 100 mg/dL ≤ FPG ≤ 125 mg/dL or 140 mg/dL ≤ PG ≤ 199 mg/dL at 2 hours after 75 g oral glucose load or 5.7% ≤ ≤ 6.4%
  3. Self-reported history of at least one failed attempt at weight control using diet and exercise therapy prior to the screening visit
  4. Able to agree to and follow the reduced-calorie diet and exercise therapy recommended in this study during the study period
  5. Agrees to use a medically appropriate method of (including medically infertile conditions) during the study period

Exclusion criteria

Exclusion Criteria:

  1. Body weight change exceeding 5 kg within 3 months of the screening visit
  2. Diabetes (Type 1, Type 2, etc.) or ≥ 6.5% at the screening visit
  3. Received any of the following medications or treatments within 3 months of the screening visit

    ① Obesity-related medications (such as GLP-1 receptor agonists) or medications including over-the-counter drugs, herbal medicines, or health functional foods for weight control

    ② Received hypoglycemic agent or requires continuous administration during the study period

    ③ Received systemic for 30 consecutive days or more, or requires continuous administration during the study period

    ④ Received other medications that cause significant body weight changes or requires continuous administration during the study period (e.g.: antipsychotics, tricyclic antidepressants, selective serotonin reuptake inhibitors, noradrenergic and specific serotonergic antidepressant, mood stabilizers (lithium), anticonvulsants, serotonin antagonists, first-generation antihistamines, etc.)

  4. Diagnosed with obesity due to endocrine disorders (hypothalamic obesity, Cushing's syndrome, insulinoma, adult growth hormone deficiency, hypothyroidism, etc.)
  5. Diagnosed with obesity due to genetic variations and congenital disorders

    • Obesity-causing genes: ob, db, Proopiomelanocortin (POMC), Melanocortin 4 receptor (MC4R) genes, etc.
    • Congenital disorders: Prader-Willi syndrome, Laurence-Moon-Biedl syndrome, Alström syndrome, Cohen syndrome, Carpenter syndrome, etc.
  6. History of bariatric surgery (e.g., adjustable gastric banding, sleeve gastrectomy, Roux-en-Y gastric bypass, biliopancreatic diversion/duodenal switch, etc.) or device procedures, or plans for such during the study period

    • However, those who have had devices (e.g., gastric band, intragastric balloon) removed for more than 1 year can participate
    • Those who have had liposuction or abdominoplasty for more than 1 year can participate
  7. gastrointestinal disorders (e.g., gastroparesis, gastric outlet obstruction, peptic ulcer, severe gastroesophageal reflux disease)
  8. History (including family history) of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2), or results of clinical laboratory test at the screening visit meeting the following:

    • Calcitonin ≥ 100 ng/L
    • TSH \< 0.6 mIU/L or TSH > 6.8 mIU/L (However, subjects being treated for hypothyroidism with 0.6 mIU/L ≤ TSH ≤ 6.8 mIU/L, taking stable doses of thyroid hormonal preparation for 3 months prior to the screening visit and unlikely to have dose changes during the study period can participate)
  9. History of acute or chronic pancreatitis, or results of clinical laboratory test at the screening visit meeting the following:

    - Amylase or Lipase > 3 times the

  10. Severe hepatic impairment or results of clinical laboratory test at the screening visit meeting the following:

    - or ALT > 3 times the upper limit of normal or Total > 2 times the upper limit of normal

  11. Severe renal impairment ( \< 30mL/min/1.73m2)
  12. Uncontrolled hypertension (sitSBP ≥ 160 mmHg or sitDBP ≥ 100 mmHg) at the screening visit
  13. Answered "yes" to question 4 or 5 in the suicidal ideation section of the Columbia-Suicide Severity Rating Scale (C-SSRS) at the screening visit or history of suicide attempt
  14. Score of 15 or higher on the Patient Health Questionnaire-9 (PHQ-9) at the screening visit, or history of major depressive disorder with unstable state, anxiety, or other severe psychiatric disorders (schizophrenia, bipolar disorder, etc.) within 2 years
  15. History of alcohol addiction or drug abuse within 3 months of the screening visit
  16. History of malignant tumor within the last 5 years

    • Those who have been determined as complete remission (CR, pCR) of the tumor and had no relapse for 5 years or more from the date of assessment can participate
    • Those with a history of thyroid cancer (excluding MTC), basal cell and squamous cell skin cancer within the last 5 years can participate
  17. Any of the following medical histories confirmed within 3 months of the screening visit

    • Heart failure of class IV
    • Coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI)
    • Ischemic heart disease (acute myocardial infarction, unstable angina, etc.). However, if the condition has been stable for 6 months or more from the screening visit, participation is possible at the investigator's discretion
    • Severe cerebrovascular disease (cerebral infarction, cerebral hemorrhage, etc.), (TIA). However, if the condition has been stable for 6 months or more from the screening visit, participation is possible at the investigator's discretion
  18. History of non-arteritic anterior ischemic optic neuropathy (NAION)
  19. History of resistance or to product class drugs (GLP analogues) or history of multi-drug allergies
  20. Requires administration of medications during the study period
  21. Received other investigational products within 30 days or 5 times the half-life (whichever is longer) if the half-life is known, prior to the screening visit
  22. Positive for , antibody, or antibody at the screening visit

    - However, those who are HCV-Ab positive but confirmed negative in HCV-RNA test can participate

  23. Hematological conditions that may interfere with HbA1c measurement (e.g.: hemolytic anemia, hemoglobinopathies)
  24. Scheduled for surgery requiring hospitalization during the study period or requires surgical treatment
  25. Positive pregnancy test, pregnant or lactating women
  26. Considered inappropriate as a study subject by the investigator for other reasons
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    IN-B00009

    Drug: IN-B00009

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugIN-B00009

    Test drug

  • DrugPlacebo

    Placebo drug

06

What researchers measure

Primary outcomes

  1. Percent change in body weight from baseline at Week 40

    Time frame: Baseline, 40 weeks

  2. Proportion of subjects with ≥5% body weight loss from baseline at Week 40

    Time frame: Baseline, 40 weeks

Secondary outcomes

  1. Percent change in body weight from baseline at Week 24

    Time frame: Baseline, 24 weeks

  2. Proportion of subjects with ≥5% body weight loss from baseline at Week 24

    Time frame: Baseline, 24 weeks

  3. Proportion of subjects with ≥10% body weight loss from baseline at Week 24 and Week 40

    Time frame: Baseline, 24 weeks, 40 weeks

  4. Proportion of subjects with ≥15% body weight loss from baseline at Week 24 and Week 40

    Time frame: Baseline, 24 weeks, 40 weeks

  5. Change in body weight from baseline at Week 24 and Week 40

    Time frame: Baseline, 24 weeks, 40 weeks

  6. Change in BMI from baseline at Week 24 and Week 40

    Time frame: Baseline, 24 weeks, 40 weeks

  7. Change in waist circumference from baseline at Week 24 and Week 40

    Time frame: Baseline, 24 weeks, 40 weeks

  8. Change in glucose metabolism parameters from baseline at Week 24 and Week 40

    Time frame: Baseline, 24 weeks, 40 weeks

  9. Percent change in lipids from baseline at Week 24 and Week 40

    Time frame: Baseline, 24 weeks, 40 weeks

  10. Change in blood pressure(systolic, diastolic) from baseline at Week 24 and Week 40

    Time frame: Baseline, 24 weeks, 40 weeks

  11. Change in IWQOL-Lite-CT(Impact of Weight on Quality of Life-Lite for Clinical Trials version) (Physical function domain) from baseline at Week 24 and Week 40

    Time frame: Baseline, 24 weeks, 40 weeks

  12. Change in SF-36(36-Item Short Form Survey) scores from baseline at Week 24 and Week 40

    Time frame: Baseline, 24 weeks, 40 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Dec 2026, 15 months later.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 15 months is below that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2025
First posted
Sep 25, 2025
StartEst.
Sep 22, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Sep 30, 2027
Last update
Sep 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07192263
Responsible party
Sponsor
First posted
Sep 25, 2025
Start date
Sep 22, 2025 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Sep 25, 2025

Study contacts

Eunji Park
Contact
eunji.park@inno-n.com
82-031-5176-4656
Eunji Kim
Contact
eunji.kim24@inno-n.com
82-031-5176-4652
Cheol-Young Park
principal investigator · Kangbuk Samsung Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion